Severe/JJ
5-fluorouracil/NN
toxicity/NN
secondary/JJ
to/TO
dihydropyrimidine/NN
dehydrogenase/NN
deficiency/NN
./.
=====
A/DT
potentially/RB
more/RBR
common/JJ
pharmacogenetic/JJ
syndrome/NN
./.

This/DT
study/NN
describes/VBZ
the/DT
inheritance/NN
of/IN
a/DT
defect/NN
in/IN
pyrimidine/NN
catabolism/NN
and/CC
its/PRP$
association/NN
with/IN
drug-induced/JJ
toxicity/NN
in/IN
a/DT
patient/NN
receiving/VBG
5-fluorouracil/NN
(/(
FUra/NN
)/)
as/IN
adjuvant/JJ
chemotherapy/NN
for/IN
breast/NN
carcinoma/NN
./.
=====
The/DT
study/NN
population/NN
included/VBD
the/DT
affected/VBN
patient/NN
(/(
proband/NN
)/)
,/,
nine/CD
of/IN
her/PRP$
blood/NN
relatives/NNS
,/,
and/CC
seven/CD
healthy/JJ
volunteers/NNS
./.
=====
The/DT
activity/NN
of/IN
dihydropyrimidine/NN
dehydrogenase/NN
(/(
DPD/NN
)/)
,/,
the/DT
initial/JJ
enzyme/NN
of/IN
pyrimidine/NN
(/(
and/CC
FUra/NN
)/)
catabolism/NN
,/,
in/IN
peripheral/JJ
blood/NN
mononuclear/JJ
cells/NNS
was/VBD
measured/VBN
in/IN
each/DT
subject/NN
by/IN
a/DT
specific/JJ
radiometric/JJ
assay/NN
using/VBG
FUra/NN
as/IN
the/DT
substrate/NN
./.
=====
The/DT
proband/NN
had/VBD
no/DT
detectable/JJ
DPD/NN
activity/NN
./.
=====
When/WRB
enzyme/NN
levels/NNS
in/IN
the/DT
proband/NN
and/CC
relatives/NNS
were/VBD
compared/VBN
with/IN
that/DT
in/NN
controls/NNS
,/,
an/DT
autosomal/JJ
recessive/JJ
pattern/NN
of/IN
inheritance/NN
was/VBD
demonstrated/VBN
./.
=====
This/DT
is/VBZ
the/DT
third/JJ
patient/NN
with/IN
severe/JJ
FUra/NN
toxicity/NN
secondary/JJ
to/TO
an/DT
alteration/NN
in/IN
pyrimidine/NN
catabolism/NN
and/CC
the/DT
second/NN
from/IN
our/PRP$
clinic/NN
population/NN
suggesting/VBG
that/IN
the/DT
frequency/NN
of/IN
this/DT
genetic/JJ
defect/NN
may/MD
be/VB
greater/JJR
than/IN
previously/RB
thought/VBN
./.
=====
Monitoring/VBG
DPD/NN
activity/NN
may/MD
be/VB
important/JJ
in/IN
the/DT
management/NN
of/IN
patients/NNS
experiencing/VBG
severe/JJ
toxicity/NN
secondary/JJ
to/TO
FUra/NN
chemotherapy/NN
./.